Empowered Funds LLC purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 91,771 shares of the medical equipment provider's stock, valued at approximately $8,210,000. Empowered Funds LLC owned about 0.13% of Lantheus as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of LNTH. Cetera Investment Advisers raised its stake in Lantheus by 34.8% during the second quarter. Cetera Investment Advisers now owns 29,592 shares of the medical equipment provider's stock worth $2,376,000 after acquiring an additional 7,640 shares in the last quarter. GAMMA Investing LLC lifted its stake in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after purchasing an additional 146 shares during the last quarter. CWM LLC boosted its position in Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 290 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Lantheus by 57.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider's stock valued at $139,000 after acquiring an additional 460 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.
Analyst Ratings Changes
A number of brokerages recently weighed in on LNTH. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. Truist Financial reiterated a "buy" rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.86.
Get Our Latest Stock Analysis on Lantheus
Insider Buying and Selling
In related news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.50% of the stock is owned by insiders.
Lantheus Stock Down 0.2 %
Lantheus stock traded down $0.14 during mid-day trading on Thursday, hitting $81.96. 775,901 shares of the stock were exchanged, compared to its average volume of 792,759. The stock has a market capitalization of $5.70 billion, a price-to-earnings ratio of 13.64 and a beta of 0.44. Lantheus Holdings, Inc. has a 12 month low of $55.01 and a 12 month high of $126.89. The firm's fifty day simple moving average is $91.76 and its two-hundred day simple moving average is $98.13.
About Lantheus
(
Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Featured Articles
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
